DrugPatentWatch Database Preview
Drugs in Development Information for Crenolanib
» See Plans and Pricing
What is the drug development status for Crenolanib?
Crenolanib is an investigational drug.
There have been 17 clinical trials for Crenolanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2015.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Arog Pharmaceuticals, Inc., St. Jude Children's Research Hospital, and University of Ulm.
There are ten US patents protecting this investigational drug and one hundred and forty-three international patents.
Summary for Crenolanib
| US Patents | 10 |
| International Patents | 143 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 382 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-04-01) |
| Vendors | 61 |
Recent Clinical Trials for Crenolanib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia | Arog Pharmaceuticals, Inc. | Phase 2 |
| Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | Arog Pharmaceuticals, Inc. | Phase 3 |
| Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | Arog Pharmaceuticals, Inc. | Phase 3 |
Clinical Trial Summary for Crenolanib
Top disease conditions for Crenolanib
Top clinical trial sponsors for Crenolanib
US Patents for Crenolanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Crenolanib | Start Trial | Method of inhibiting mutant C-KIT | Arog Pharmaceuticals, Inc. (Dallas, TX) | Start Trial |
| Crenolanib | Start Trial | Benzoimidazole derivatives useful as antiproliferative agents | Pfizer Inc (New York, NY) | Start Trial |
| Crenolanib | Start Trial | Processes for the preparation of benzoimidazole derivatives | Pfizer Inc (New York, NY) | Start Trial |
| Crenolanib | Start Trial | Method of inhibiting constitutively active phosphorylated FLT3 kinase | AROG Pharmaceuticals, LLC (Dallas, TX) | Start Trial |
| Crenolanib | Start Trial | Crenolanib for treating FLT3 mutated proliferative disorders | AROG PHARMACEUTICALS, INC. (Dallas, TX) | Start Trial |
| Crenolanib | Start Trial | Crenolanib for treating FLT3 mutated proliferative disorders | AROG PHARMACEUTICALS, INC. (Dallas, TX) | Start Trial |
| Crenolanib | Start Trial | Method of inhibiting mutant C-kit | AROG PHARMACEUTICALS, INC. (Dallas, TX) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Crenolanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Crenolanib | Australia | AU2013204841 | 2032-09-26 | Start Trial |
| Crenolanib | Canada | CA2812258 | 2032-09-26 | Start Trial |
| Crenolanib | China | CN103655563 | 2032-09-26 | Start Trial |
| Crenolanib | China | CN109010340 | 2032-09-26 | Start Trial |
| Crenolanib | Japan | JP2014065696 | 2032-09-26 | Start Trial |
| Crenolanib | Japan | JP6042157 | 2032-09-26 | Start Trial |
| Crenolanib | South Korea | KR101886006 | 2032-09-26 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
